A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

It is not clear how AS01 might help lower the risk of dementia, but Oxford University said lab studies show that the adjuvant ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

A new study shows that a vaccine against respiratory syncytial virus is associated with a 29% reduction in dementia risk in ...

New research suggests vaccines against "potentially serious and life-threatening infections" could offer double protection ...

Some vaccines may reduce the risk of dementia through a double effect in which the jabs help protect the brain through their ...

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved a 200 mg/mL autoinjector of Benlysta, a B-lymphocyte ...

GSK plc has announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted the company's regulatory ...

Japan’s MHLW accepts GSK’s regulatory application to expand use of RSV vaccine, Arexvy, in adults aged 18-49 at increased risk of severe RSV disease: London, UK Saturday, June ...

Japan’s Ministry of Health, Labour and Welfare (MHLW) has accepted UK pharma major GSK’s regulatory application to expand the ...

(Alliance News) - GSK PLC on Friday announced that Japan has accepted a regulatory application to expand the use of its respiratory syncytial virus [RSV] vaccine Arexvy.

London stocks were set to rise at the open on Friday, recouping some of the previous day’s losses as investors continued to ...